"Our next objective in Idera's autoimmune disease program is to initiate a Phase 2 study of IMO-8400, a first-in-class TLR7, 8 and 9 antagonist, in patients with moderate-to-severe plaque psoriasis during the current quarter.

Idera Pharmaceuticals (NASDAQ: IDRA) today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index (PASI) scores in ...

The gross proceeds to Idera Pharmaceuticals from this offering were $16.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Idera and excluding the proceeds, if any, from the exercise of ...

Idera Pharmaceuticals, Inc. is engaged in the discovery and development of deoxyribonucleic acid (NASDAQ: IDRA) and ribonucleic acid (RNA)-based drug candidates targeted to Toll-Like Receptors (TLRs), to treat infectious diseases, autoimmune and ...

Idera Pharmaceuticals is a clinical stage biotechnology company engaged in the discovery and development of novel synthetic DNA- and RNA-based drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors.

... IDERA PHARMACEUTICALS INC Q1 BIOTECHNOLOGY USD -0.17 -0.15 0.02 0.0 0.0 0.0 INTERTAPE POLYMER Q1 UNDESIGNATED CAPITAL USD 0.21 0.24 0.03 196.9 196.7 -0.2 ISORAY INC Q3 MEDICAL SUPPLIES USD -0.03 -0.02 0.01 1.1 1.3 0.1 ...

The fully marketed secondary offerings that priced that week include Idera Pharmaceuticals Inc., which raised $17 million; Macquarie Infrastructure Co.

... S.r.l. -- Eli Lilly and Company -- Genentech, Inc. -- Genesis Research and Development Corporation Ltd. -- GlaxoSmithKline plc -- Hadasit Medical Research Services & Development Lt -- IMMUNOMEDICS, INC -- Idera Pharmaceuticals, Inc. -- Immupharma ...

The shares remained unchanged at $45.42. Bluefly Inc. : Approximately 90,600 shares changed hands, a 803.9 percent increase over its 65-day average volume.